Comparison Overview

Hikma Pharmaceuticals

VS

MACLEODS PHARMACEUTICALS LTD.

Hikma Pharmaceuticals

1 New Burlington Place, London, W1S 2HR, GB
Last Update: 2025-12-11
View Profile
Between 750 and 799
http://www.hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 10,222
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0
View Profile

MACLEODS PHARMACEUTICALS LTD.

304, Atlanta Arcade Marol Church Road, Andheri East, Mumbai, Maharashtra, IN, 400059
Last Update: 2025-12-10
Between 750 and 799
https://www.macleodspharma.com

A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 11,522
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/hikma-pharmaceuticals.jpeg
Hikma Pharmaceuticals
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/macleods-pharmaceuticals-ltd..jpeg
MACLEODS PHARMACEUTICALS LTD.
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Hikma Pharmaceuticals
100%
Compliance Rate
0/4 Standards Verified
MACLEODS PHARMACEUTICALS LTD.
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Hikma Pharmaceuticals in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for MACLEODS PHARMACEUTICALS LTD. in 2025.

Incident History — Hikma Pharmaceuticals (X = Date, Y = Severity)

Hikma Pharmaceuticals cyber incidents detection timeline including parent company and subsidiaries

Incident History — MACLEODS PHARMACEUTICALS LTD. (X = Date, Y = Severity)

MACLEODS PHARMACEUTICALS LTD. cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/hikma-pharmaceuticals.jpeg
Hikma Pharmaceuticals
Incidents

No Incident

https://images.rankiteo.com/companyimages/macleods-pharmaceuticals-ltd..jpeg
MACLEODS PHARMACEUTICALS LTD.
Incidents

No Incident

FAQ

MACLEODS PHARMACEUTICALS LTD. company demonstrates a stronger AI Cybersecurity Score compared to Hikma Pharmaceuticals company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, MACLEODS PHARMACEUTICALS LTD. company has disclosed a higher number of cyber incidents compared to Hikma Pharmaceuticals company.

In the current year, MACLEODS PHARMACEUTICALS LTD. company and Hikma Pharmaceuticals company have not reported any cyber incidents.

Neither MACLEODS PHARMACEUTICALS LTD. company nor Hikma Pharmaceuticals company has reported experiencing a ransomware attack publicly.

Neither MACLEODS PHARMACEUTICALS LTD. company nor Hikma Pharmaceuticals company has reported experiencing a data breach publicly.

Neither MACLEODS PHARMACEUTICALS LTD. company nor Hikma Pharmaceuticals company has reported experiencing targeted cyberattacks publicly.

Neither Hikma Pharmaceuticals company nor MACLEODS PHARMACEUTICALS LTD. company has reported experiencing or disclosing vulnerabilities publicly.

Neither Hikma Pharmaceuticals nor MACLEODS PHARMACEUTICALS LTD. holds any compliance certifications.

Neither company holds any compliance certifications.

Neither Hikma Pharmaceuticals company nor MACLEODS PHARMACEUTICALS LTD. company has publicly disclosed detailed information about the number of their subsidiaries.

MACLEODS PHARMACEUTICALS LTD. company employs more people globally than Hikma Pharmaceuticals company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Hikma Pharmaceuticals nor MACLEODS PHARMACEUTICALS LTD. holds SOC 2 Type 1 certification.

Neither Hikma Pharmaceuticals nor MACLEODS PHARMACEUTICALS LTD. holds SOC 2 Type 2 certification.

Neither Hikma Pharmaceuticals nor MACLEODS PHARMACEUTICALS LTD. holds ISO 27001 certification.

Neither Hikma Pharmaceuticals nor MACLEODS PHARMACEUTICALS LTD. holds PCI DSS certification.

Neither Hikma Pharmaceuticals nor MACLEODS PHARMACEUTICALS LTD. holds HIPAA certification.

Neither Hikma Pharmaceuticals nor MACLEODS PHARMACEUTICALS LTD. holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

NXLog Agent before 6.11 can load a file specified by the OPENSSL_CONF environment variable.

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 8.1
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:C/C:H/I:H/A:H
References
Description

uriparser through 0.9.9 allows unbounded recursion and stack consumption, as demonstrated by ParseMustBeSegmentNzNc with large input containing many commas.

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 2.9
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:L
References
Description

A vulnerability was detected in Mayan EDMS up to 4.10.1. The affected element is an unknown function of the file /authentication/. The manipulation results in cross site scripting. The attack may be performed from remote. The exploit is now public and may be used. Upgrading to version 4.10.2 is sufficient to fix this issue. You should upgrade the affected component. The vendor confirms that this is "[f]ixed in version 4.10.2". Furthermore, that "[b]ackports for older versions in process and will be out as soon as their respective CI pipelines complete."

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss2
Base: 5.0
Severity: LOW
AV:N/AC:L/Au:N/C:N/I:P/A:N
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:L/A:N
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

MJML through 4.18.0 allows mj-include directory traversal to test file existence and (in the type="css" case) read files. NOTE: this issue exists because of an incomplete fix for CVE-2020-12827.

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 4.5
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:C/C:L/I:N/A:L
References
Description

A half-blind Server Side Request Forgery (SSRF) vulnerability exists in kube-controller-manager when using the in-tree Portworx StorageClass. This vulnerability allows authorized users to leak arbitrary information from unprotected endpoints in the control plane’s host network (including link-local or loopback services).

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 5.8
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:H/UI:N/S:C/C:H/I:N/A:N
References